Part 7/8:
Next week promises a turbulent period for the sector, as market participants prepare for announcements related to the Most Favored Nation (MFN) status, the Inflation Reduction Act (IRA), and other policy initiatives targeting drug pricing and trade policies.
It is essential to recognize that headlines often diverge from practical implementation. Policymakers may announce regulations that appear impactful but are later modified or delayed in execution. Therefore, investors and industry stakeholders are preparing to interpret not just policy statements but also their real-world impacts on business models.